BPC-157 UK: Research Reference 2026

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of the human gastric protein Body Protection Compound (BPC). The peptide has been investigated in preclinical research for its effects on tissue regeneration, wound healing, and gastrointestinal integrity.

The sequence is a partial replica of the 193-amino-acid BPC protein found in human gastric juice. The synthetic 15-mer retains the bioactive domain of the parent protein and is more stable and bioavailable than the full-length sequence.

For UK research laboratories, BPC-157 serves as a reference compound for studies examining tissue regeneration, angiogenesis, and the protective mechanisms of gastric-derived peptides. The peptide is not licensed as a medicine and is supplied for research use only.

BPC-157 is a pentadecapeptide with the following structural characteristics:

• Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids)
• Molecular weight: Approximately 1,419 Da
• N-terminus: Free amine
• C-terminus: Free carboxyl
• Origin: Synthetic analogue of a partial sequence from human gastric BPC

The peptide contains multiple proline residues, which confer structural rigidity and resistance to proteolytic degradation. The absence of complex post-translational modifications contributes to stability during storage and handling. The relatively small size and simple sequence facilitate reproducible synthesis and characterisation.

BPC-157 operates through several mechanisms in cellular and in vitro models:

Angiogenesis Promotion

In cellular studies, BPC-157 upregulates vascular endothelial growth factor (VEGF) and stimulates endothelial cell proliferation and migration. The peptide promotes formation of new blood vessels in wound-healing models, supporting tissue perfusion and regenerative processes. This angiogenic activity is examined in endothelial cell cultures and ex vivo vessel sprouting assays.

Tendon and Ligament Healing

In fibroblast and tenocyte cultures, BPC-157 increases collagen synthesis and extracellular matrix deposition. The peptide stimulates fibroblast migration and proliferation in wound-healing assays, supporting the cellular basis for connective tissue repair. Research models examine tendon explant healing and fibroblast scratch assays.

Gastrointestinal Protection

Derived from a gastric protein, BPC-157 has been studied in gastrointestinal epithelial cell models. In cellular studies, the peptide maintains epithelial integrity under stress conditions and supports mucosal barrier function. Research examines effects on tight junction proteins and epithelial cell viability.

Anti-Inflammatory Signalling

BPC-157 modulates inflammatory mediator production in cellular models. The peptide reduces pro-inflammatory cytokine secretion in activated macrophage cultures and modulates NF-κB signalling. These anti-inflammatory effects are examined in the context of tissue repair and chronic inflammation models.

Nitric Oxide Pathway

The peptide interacts with the nitric oxide system in endothelial and vascular models. BPC-157 upregulates endothelial nitric oxide synthase (eNOS) expression and increases NO production, which supports vasodilation and tissue perfusion in regenerative processes.

BPC-157 is employed across multiple research domains in UK laboratories:

Regenerative Medicine Research

In vitro studies examine BPC-157's effects on tissue regeneration, wound healing, and angiogenesis. Researchers use cellular models to study the peptide's effects on fibroblast migration, collagen synthesis, and endothelial tube formation.

Musculoskeletal Research

Tendon, ligament, and bone cell cultures are used to examine BPC-157's effects on connective tissue healing. Research questions address whether the peptide accelerates matrix deposition, improves cellular viability under stress, and supports tissue integration.

Gastrointestinal Research

Epithelial cell models examine BPC-157's effects on mucosal integrity, tight junction maintenance, and epithelial repair. The peptide's gastric origin makes it relevant for research into gastrointestinal protective mechanisms.

Vascular Biology

Endothelial cell models examine BPC-157's effects on angiogenesis, vessel formation, and vascular permeability. The peptide's interaction with VEGF and NO pathways creates research questions about vascular regeneration.

Comparative Healing Peptides

BPC-157 is compared to other regenerative peptides (TB-500, GHK-Cu) in cellular studies. Research questions examine whether different peptide mechanisms produce synergistic or additive effects in tissue repair models.

UK research laboratories employ several standard cellular models for BPC-157 studies:

Fibroblast Wound Healing

Primary fibroblasts and fibroblast cell lines are used in scratch assays to measure migration and proliferation in response to BPC-157. Endpoints include wound closure rate, collagen I/III deposition, and α-SMA expression.

Endothelial Tube Formation

HUVEC and other endothelial cell lines are used in Matrigel tube formation assays to examine angiogenic effects. Endpoints include tube length, branch points, and network complexity. VEGF and NO production are measured in parallel.

Tendon Explant Cultures

Ex vivo tendon and ligament explants are maintained in culture to examine tissue-level healing. BPC-157 is added to culture media, and endpoints include tissue strength, collagen organisation, and cell viability.

Epithelial Barrier Integrity

Caco-2 and other intestinal epithelial cell lines are used to measure transepithelial electrical resistance (TEER) and tight junction protein expression (claudin, occludin, ZO-1) in response to BPC-157 under stress conditions.

Macrophage Inflammation

RAW 264.7 and primary macrophages are activated with LPS, then treated with BPC-157 to examine effects on cytokine production (TNF-α, IL-6, IL-10) and NF-κB activation.

BPC-157's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens have not identified significant cytotoxicity at research-relevant concentrations.

In animal toxicology studies, the peptide has been well tolerated at standard research doses. The gastric origin of the parent protein suggests low inherent toxicity, though the synthetic peptide's effects may differ from the native sequence. No organ-specific toxicity has been reported at standard doses.

The peptide's stability in gastric juice has been examined in vitro, with resistance to pepsin degradation reported. This stability may contribute to oral bioavailability in animal models, though cellular and in vitro studies typically use direct application.

Standard laboratory precautions apply: BPC-157 is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only.

BPC-157 is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation:

• Reconstitution: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations
• Concentration: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements
• Storage: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light
• Stability: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C
• Solubility: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution
• Gastric stability: The peptide shows resistance to pepsin degradation in vitro, though this is assay-dependent

The peptide's stability in acidic environments may be relevant for gastrointestinal research models. Standard peptide handling precautions apply.

BPC-157 is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA.

For UK research laboratories, BPC-157 is available as a research-grade reference material. Sourcing should include:

• Certificate of Analysis confirming ≥98% purity (HPLC)
• Mass spectrometry identity confirmation (molecular weight ~1,419 Da)
• Batch-specific testing documentation
• Appropriate storage and shipping conditions (cold chain)
• Research-use-only labelling

Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling.